ストックスクリーナーアプリを入手
1.31
2.96%
-0.04
アフターアワーズ：
1.28
-0.03
-2.29%
前日終値:
$1.35
開ける：
$1.33
24時間の取引高:
400.04K
Relative Volume:
0.29
時価総額：
$6.27M
収益：
-
当期純損益:
$-27.39M
株価収益率:
-0.7796
EPS:
-1.6803
ネットキャッシュフロー:
$-2.09M
1週間 パフォーマンス:
-0.76%
1か月 パフォーマンス:
-65.53%
6か月 パフォーマンス:
-90.90%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.20
$1.36
1週間の範囲:
$1.20
$1.49
52週間の値動き範囲:
$1.20
$84.00
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
名前
Aspire Biopharma Holdings Inc
セクター
電話
561-704-8527
住所
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.31 | 6.47M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aspire Biopharma Holdings Inc (ASBP) 最新ニュース
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Worcester Telegram
Aspire Biopharma Announces Private Placement to Strengthen Finances - TipRanks
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - BlueRidgeNow.com
Aspire Biopharma Holdings Signs Multiple Material Agreements - TradingView
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) - ACCESS Newswire
New Zofran-style powder aims to bring IV-speed nausea relief at home - Stock Titan
Major Financial Concerns Loom as Aspire Biopharma Troubles Deepen - StocksToTrade
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements - ACCESS Newswire
$21M cash boost aims to keep Aspire Biopharma on Nasdaq - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - SouthCoastToday.com
Aspire Biopharma regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Nigeria
Aspire Biopharma Provides Q3 2025 Business Update - Corpus Christi Caller-Times
Aspire Biopharma regains Nasdaq minimum bid price compliance - MSN
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bluefield Daily Telegraph
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings files for Series A convertible preferred stock on Nasdaq - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - accessnewswire.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - DelmarvaNow.com
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages - Yahoo Finance
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - The Times-Mail
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Finviz
Caffeine stick packs hit Palm Springs resorts ahead of Coachella - Stock Titan
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - The Clarion-Ledger
ASBPWAspire Biopharma Holdings Inc Latest Stock News & Market Updates - stocktitan.net
Aspire Biopharma Holdings raises $2 million through debenture sale By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings Inc (ASBP) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):